Skip to main content

Table 4 Association study of lncRNAs expression and clinicopathological data of patients

From: Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues

 

FAS-AS1 up-regulation

FAS-AS1 down-regulation

P value

HOTAIRM1 up-regulation

HOTAIRM1 Down-regulation

P value

NEAT1 up-regulation

NEAT1 down-regulation

P value

PVT1 up-regulation

PVT1 down-regulation

P value

THRIL up-regulation

THRIL down-regulation

P value

TUG1 up-regulation

TUG1 down-regulation

P value

GAS5 up-regulation

GAS5 down-regulation

P value

Age

1

  

0.48

  

0.48

  

0.723

  

0.476

  

0.723

  

0.723

 < 60 years

8(50%)

8(50%)

 

9 (56.3%)

7(43.8%)

 

9(56.2%)

7(43.8)

 

9(56.3%)

7(43.8%)

 

10(62.5%)

6(37.5%)

 

9(56.2%)

7(43.8)

 

7(43.8%)

9(56.3%)

 

 ≥60 years

8(50%)

8(50%)

 

7(43.8%)

9(56.3%)

 

7(43.8)

9(56.2%)

 

8(50%)

8(50%)

 

8(50%)

8(50%)

 

8(50%)

8(50%)

 

8(50%)

8(50%)

 

Smoking

1

  

1

  

1

  

1

  

0.426

  

0.272

  

0.678

 Yes

13(52%)

12(48%)

 

12(48%)

13(52%)

 

12(48%)

13(52%)

 

13(52%)

12(48%)

 

13(52%)

12(48%)

 

12(48%)

13(52%)

 

11(44%)

14(56%)

 

 No

3(42.9%)

4(57.1%)

 

4(57.1%)

3(42.9%)

 

4(57.1%)

3(42.9%)

 

4(57.1%)

3(42.9%)

 

5(71.4%)

2(28.6%)

 

5(71.4%)

2(28.6%)

 

4(57.1%)

3(42.9%)

 

Stage

0.148

  

0.148

  

0.538

  

0.73

  

1

  

0.165

  

0.39

 1

6(85.7%)

1 (14.3%)

 

6(85.7%)

1 (14.3%)

 

5(71.4%)

2(28.6%)

 

3(42.9%)

4(57.1%)

 

4(57.1%)

3(42.9%)

 

6(85.7%)

1 (14.3%)

 

5(71.4%)

2(28.6%)

 

 2

4(36.4%)

7(63.6%)

 

4(36.4%)

7(63.6%)

 

5(45.5%)

6(54.5%)

 

7(63.6%)

4(36.4%)

 

6(54.5%)

5(45.5%)

 

5(45.5%)

6(54.5%)

 

4(36.4%)

7(63.6%)

 

 3

6(42.9%)

8(57.1%)

 

6(42.9%)

8(57.1%)

 

6(42.9%)

8(57.1%)

 

7(50%)

7(50%)

 

8(57.1%)

6(42.9%)

 

6(42.9%)

8(57.1%)

 

6(42.9%)

8(57.1%)

 

Subtype

0.476

  

1

  

1

  

0.688

  

0.53

  

0.688

  

0.305

 Adenocarcinoma

8(44.8%)

10(55.6%)

 

9 (50%)

9 (50%)

 

9 (50%)

9 (50%)

 

9 (50%)

9 (50%)

 

11(61.1%)

7(38.9%)

 

9 (50%)

9 (50%)

 

7(38.9%)

11(61.1%)

 

 Squamous cell carcinoma

8(57.1%)

6 (42.9%)

 

7 (50%)

7 (50%)

 

7 (50%)

7 (50%)

 

8 (57.1%)

9 (42.9%)

 

7 (50%)

7 (50%)

 

8 (57.1%)

6 (42.9%)

 

8(57.1%)

6 (42.9%)